2-oxo-1-heptanal | 2363-85-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-oxo-1-heptanal
• 英文别名: n-pentyl glyoxal；2-oxo-heptanal；Heptanon-(2)-al-(1)；Pentylglyoxal；a-Keto heptanal；2-oxoheptanal
• CAS: 2363-85-1
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: LGCRPSSTNIJLAY-UHFFFAOYSA-N

物化性质

• 沸点：
  59 °C(Press: 10 Torr)
• 密度：
  0.925±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-oxo-1-heptanal 在 calcium hydroxide 、 水 作用下， 生成 2-羟基庚酸
  参考文献：
  名称：

  Chancel, Bulletin de la Societe Chimique de France, 1950, p. 714

  摘要：

  DOI：
• 作为产物：
  描述：

  己酸甲酯 在 氢氧化钾 、 硫酸 、 sodium methylate 、 苯 作用下， 生成 2-oxo-1-heptanal
  参考文献：
  名称：

  Studies in Mixed Ester Condensations. IV. Acylations with Methyl Dimethoxyacetate¹

  摘要：

  DOI：

  10.1021/ja01597a083

文献信息

• Immunosuppressive effects of pteridine derivatives
  申请人：——

  公开号：US20030236255A1

  公开（公告）日：2003-12-25

  Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS disorder, a cell proliferative disorder, a viral infection, an immune or auto-immune disorder or a transplant rejection. Combinations of the pteridine derivatives of the invention with an immunosuppressant or immunomodulator drug, an antineoplastic drug or an antiviral agent, providing potential synergistic effects, are also disclosed.

  新型多取代的喹啉二酮（卢马嗪），以及单取代或多取代的2-硫代卢马嗪，4-硫代卢马嗪或2,4-二硫代卢马嗪，在喹啉环的1、3、6和7位上具有已披露的取代基，并且其药学上可接受的盐，在制备药物组合物中作为生物活性成分特别用于治疗或预防中枢神经系统疾病、细胞增殖障碍、病毒感染、免疫或自身免疫障碍或移植排斥。本发明的喹啉衍生物与免疫抑制剂或免疫调节剂药物、抗肿瘤药物或抗病毒药物的组合，提供潜在的协同效应。
• FLUORINATED SULFONATE ESTERS OF ARYL KETONES FOR NON-IONIC PHOTO-ACID GENERATORS
  申请人：International Business Machines Corporation

  公开号：US20180046077A1

  公开（公告）日：2018-02-15

  Non-ionic photo-acid generating (PAG) compounds were prepared that contain an aryl ketone group having a perfluorinated substituent alpha to the ketone carbonyl. The non-polymeric PAGs release a sulfonic acid when exposed to high energy radiation such as deep UV or extreme UV light. The photo-generated sulfonic acid has a low diffusion rate in an exposed resist layer subjected to a post-exposure bake (PEB) at 100° C. to 150° C., resulting in formation of good line patterns after development. At higher temperatures, the PAGs can also undergo a thermal reaction to form a sulfonic acid. The perfluorinated substituent provides improved thermal stability and hydrolytic/nucleophilic stability.

  非离子型光生酸(PAG)化合物被制备出来，它们含有一个含有全氟取代基的芳酮基团，该取代基位于酮羰基的α位置。这些非聚合PAGs在暴露于高能辐射，如深紫外或极紫外光时，会释放出磺酸。在100°C至150°C的后曝光烘烤(PEB)下，光生成的磺酸在暴露的抵抗层中具有较低的扩散速率，从而在开发后形成良好的线条图案。在较高温度下，PAGs也可以通过热反应形成磺酸。全氟取代基提供了改善的热稳定性和水解/亲核稳定性。
• [EN] HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR HIF-1 INDUIT PAR L'HYPOXIE
  申请人：US HEALTH

  公开号：WO2016164412A1

  公开（公告）日：2016-10-13

  Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF- 1 α subunit and transcriptional co-activator protein p300. Embodiments of methods for making and using the small molecule inhibitors are also disclosed.

  本文披露了针对缺氧诱导因子1（HIF-1）的小分子抑制剂及其药物组合物的实施方式。所披露的化合物通过抑制HIF-1α亚单位与转录共激活蛋白p300之间的相互作用来抑制HIF-1活性。还披露了制备和使用小分子抑制剂的方法的实施方式。
• [EN] 1,2,4-TRIAZINE-4-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZINE-4-AMINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2011095625A1

  公开（公告）日：2011-08-11

  According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.

  根据该发明提供了一种A1式化合物，可能对通过抑制A1-A2b或特别是A2a受体而得到改善的疾病或紊乱治疗有用，其中A1式化合物具有以下结构，其中，A代表Cy1或HetA；Cy1代表一个由一个、两个或三个环组成的5-至14-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy1基团可选择地被一个或多个R4a取代基所取代；HetA代表一个由一个、两个或三个环组成的5-至14-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个、两个或三个环，且该HetA基团可选择地被一个或多个R4b取代基所取代；B代表Cy2或HetB；Cy2代表一个由一个或两个环组成的3-至10-成员芳香、完全饱和或部分不饱和的碳环系统，该Cy2基团可选择地被一个或多个R4c取代基所取代；HetB代表一个由一个或两个环组成的3-至10-成员杂环基团，可能是芳香、完全饱和或部分不饱和的，并且含有从O、S和N中选择的一个或多个杂原子，该杂环基团可能包括一个或两个环，且该HetB基团可选择地被一个或多个R4d取代基所取代。
• [EN] METHOD FOR PRODUCING ALPHA-KETOALDEHYDE COMPOUND<br/>[FR] PROCÉDÉ DE PRODUCTION D'UN COMPOSÉ D'ALPHA-CÉTOALDÉHYDE
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2013018626A1

  公开（公告）日：2013-02-07

  An object of the present invention is to provide a new method for producing an ALPHA-ketoaldehyde compound from a 2-oxo-primary alcohol compound. The present invention provides a method for producing an ALPHA-ketoaldehyde compound including a step of oxidizing a 2-oxo-primary alcohol compound in the presence of platinum, a platinum compound, iron or an iron compound. The 2-oxo-primary alcohol compound is preferably a compound represented by the formula (1a), and the ALPHA-ketoaldehyde compound is preferably a compound represented by the formula (2a), wherein Ra is a C1-C6 alkyl group which may have a substituent or a C6-C20 aryl group which may have a substituent.

  本发明的一个目的是提供一种从2-氧代初级醇化合物制备ALPHA-酮醛化合物的新方法。本发明提供了一种制备ALPHA-酮醛化合物的方法，包括在铂、铂化合物、铁或铁化合物存在下氧化2-氧代初级醇化合物的步骤。2-氧代初级醇化合物最好是由式（1a）表示的化合物，而ALPHA-酮醛化合物最好是由式（2a）表示的化合物，其中Ra是一个可能带有取代基的C1-C6烷基基团或可能带有取代基的C6-C20芳基基团。